$APGE 0.53 Developing

Notable posts

• @wallstengine neutral 37 eng

  $ABBV is closing in on a nearly $11B cash deal to buy Apogee Therapeutics, per FT. The discussed deal would value $APGE at $10.9B, roughly a 60% premium to Thursday’s close, and could be announced as soon as Today. Apogee’s lead drug, zumilokibart, is being developed as a longer-acting alternative to Dupixent, with dosing studied every 3 to 6 months vs. Dupixent’s every 2 weeks. Apogee plans to start a Phase 3 trial in atopic dermatitis later this year.

  view on X →
• @tenet_research neutral 22 eng

  Tenet Market Wake-Up Summary 📷📷 June.22.26 $SPX $META $ABBV $APGE $UBER $TSLA $BA $SPCX $NFLX $MP $USAR $RCAT $LHX $LMT $RTX $GOOGL $KO $ASML $MSFT $CVX $HOOD $NOK $GETY $FRVO $POWW $VC $BWIN $SMCI $CRDO $EL $ACN $CLF $TEL $AAPL $DFTX $MPLT $MNTS $LGND @ripster47 | @TENETTRADEGROUP | @TenetCharts

  view on X →